Recombinant Cat Interleukin-2 receptor subunit alpha (IL2RA)

What is the molecular structure of feline IL2RA?

Feline IL2RA (CD25) is a type I transmembrane glycoprotein consisting of a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. The protein has a complete amino acid sequence beginning with ELCDENPPD and forms part of the high-affinity IL-2 receptor complex . The extracellular domain contains multiple binding sites for interaction with IL-2, while the intracellular domain participates in signal transduction pathways.

What expression systems are optimal for recombinant feline IL2RA production?

While E. coli systems have been used for related proteins like recombinant feline IL-2 (as seen with the IL-2 C146S mutant) , mammalian expression systems such as HEK293F cells generally provide better results for transmembrane glycoproteins like IL2RA . The glycosylation patterns achieved in mammalian systems more closely resemble native protein modifications, which are crucial for proper folding and function of IL2RA.

What are the critical parameters for maintaining recombinant feline IL2RA stability?

Recombinant feline IL2RA should be stored in an optimized buffer system, typically a Tris-based buffer with 50% glycerol . To maintain stability, the protein should be stored at -20°C for routine use or -80°C for extended storage. Researchers should avoid repeated freeze-thaw cycles and consider keeping working aliquots at 4°C for up to one week . When working with dilute solutions, addition of carrier proteins like BSA may enhance stability.

How can researchers verify the biological activity of recombinant feline IL2RA?

Biological activity can be verified through several complementary approaches:

• Binding assays: Surface plasmon resonance or ELISA-based techniques measuring direct binding to feline IL-2

• Cell proliferation assays: Measuring the ability of IL2RA to enhance IL-2-dependent T cell proliferation

• Signaling pathway activation: Assessing STAT5 phosphorylation in response to IL-2 stimulation in the presence of IL2RA

• Competition assays: Determining if soluble recombinant IL2RA can inhibit IL-2 binding to cellular receptors

What are the key research applications for recombinant feline IL2RA?

Recombinant feline IL2RA has applications in multiple research areas:

• Immunology research: Investigating T cell activation and regulatory T cell function in cats

• Comparative immunology: Studying species-specific differences in IL-2 signaling

• Disease models: Exploring roles in feline immunodeficiency syndrome, asthma, and inflammatory conditions

• Drug development: Screening potential therapeutic agents targeting IL-2/IL2RA interactions

• Diagnostic development: Creating assays to detect soluble IL2RA as a biomarker, similar to its use in human conditions

How does feline IL2RA differ from human IL2RA in structure and function?

While both feline and human IL2RA share similar domain organizations, there are notable species-specific differences. Experimental evidence with recombinant feline IL-2 demonstrates that it promotes proliferation of feline cells but not human cells, suggesting species-specific receptor interactions . This species specificity likely extends to structure-function relationships of IL2RA itself, though detailed comparative binding studies between feline and human IL2RA would be needed to fully characterize these differences.

Can human IL-2 interact functionally with feline IL2RA?

The species-specific nature of IL-2/IL2R interactions suggests limited cross-reactivity between human IL-2 and feline receptors. Studies have shown that recombinant human IL-2 can promote proliferation of both human and feline leukocytes, while recombinant feline IL-2 only activates feline cells . This partial cross-reactivity indicates that human IL-2 may have some functional interaction with the feline receptor complex, but likely with different binding kinetics and signaling efficiency compared to feline IL-2.

How can enhancer regions of the IL2RA gene be analyzed to understand expression regulation?

Advanced techniques for IL2RA enhancer analysis include:

• CRISPR-based enhancer mapping: Using genome editing to delete specific enhancer regions and observe effects on IL2RA expression

• ChIP-seq analysis: Identifying transcription factor binding sites within enhancer regions

• Chromosome conformation capture: Analyzing physical interactions between enhancer elements and the IL2RA promoter

Recent research has revealed distinct super-enhancer elements that differentially control Il2ra gene expression in T cells, with separate intronic and upstream regions contributing differently to expression patterns . A study on human cells showed that a disease-associated enhancer variant delayed IL2RA gene activation timing in response to specific signals, demonstrating the critical role of enhancers in temporal gene regulation .

How do mutations in IL2RA affect immune function and disease susceptibility?

Multiple studies have identified IL2RA polymorphisms associated with various diseases:

These findings suggest IL2RA mutations can affect receptor expression timing, levels, and function, with implications for autoimmune diseases and infectious disease susceptibility .

What approaches exist for engineering IL2RA for therapeutic applications?

Engineering strategies for IL2RA and its ligands include:

• Receptor masking: Creating masked versions that only become active in specific microenvironments, similar to the PD-1-targeted, receptor-masked IL-2 immunocytokine

• Affinity modulation: Designing variants with altered binding affinities by modifying key residues at interaction interfaces

• Temporal regulation: Engineering receptor variants with modified trafficking properties to alter signaling duration

• Cell-type specificity: Creating variants that preferentially activate specific immune cell subsets

For example, researchers have developed IL-2 mutants with reduced IL2RA affinity by substituting key residues like K35A, F42A, and E61A, which could be adapted to create engineered feline IL2RA variants with modified properties .

How can researchers address issues with recombinant IL2RA activity loss?

Activity loss can be addressed through several approaches:

• Buffer optimization: Determine if the current buffer composition adequately maintains protein stability

• Expression system selection: For glycoproteins like IL2RA, mammalian expression systems may preserve more native-like structure and function

• Proper reconstitution: Follow specific reconstitution protocols for lyophilized protein

• Functional complex formation: For binding studies, ensure availability of all three receptor components (α, β, γ) which may be necessary for high-affinity interactions

What are effective strategies for optimizing receptor complex formation in experimental systems?

Based on literature describing IL-2 receptor biology, researchers should consider:

• Co-expression strategies: When studying receptor function, co-express all three chains (IL2RA, IL2RB, IL2RG) to enable proper complex formation

• Stoichiometry control: Maintain appropriate ratios of the three receptor components

• Sequential binding studies: Exploit the natural binding sequence where IL2RA captures IL-2 and presents it to IL2RB/IL2RG

• Membrane environment consideration: Use cell-based systems or lipid nanodiscs to maintain native membrane context for transmembrane receptors

Studies have demonstrated that immobilized IL-2R complexes containing all three receptor components show dramatically higher binding affinity for IL-2 compared to individual chains or partial complexes .

How might single-cell approaches advance our understanding of feline IL2RA function?

Single-cell technologies could reveal:

• Expression heterogeneity: Identifying subpopulations of cells with varying IL2RA expression levels

• Temporal dynamics: Capturing the kinetics of IL2RA upregulation following T cell activation

• Correlation with function: Relating IL2RA expression levels to functional outcomes at the single-cell level

• Regulatory network interactions: Understanding how IL2RA expression correlates with other genes in immune response networks

What emerging technologies might enable novel IL2RA-based therapeutic approaches?

Future directions may include:

• Bispecific antibodies: Creating molecules that target both IL2RA and tumor-associated antigens

• CAR-T approaches: Using IL2RA-targeted chimeric antigen receptors for specific immune cell targeting

• Receptor-cytokine fusions: Developing novel fusion proteins combining IL2RA with cytokines for targeted immune modulation

• Nanobody-based modulators: Employing smaller antibody fragments for better tissue penetration and novel binding epitopes

• Conditional activation systems: Engineering IL2RA variants that respond only under specific disease-associated conditions

The development of a PD-1-targeted, receptor-masked IL-2 immunocytokine demonstrates the potential for creating conditionally active cytokine receptor systems that could be adapted to IL2RA-based therapeutics .

What are best practices for comparing feline IL2RA with human IL2RA in research studies?

For valid species comparisons:

• Standardized assay conditions: Use identical experimental conditions when comparing across species

• Equivalent expression systems: Produce both proteins in the same expression system to minimize system-specific differences

• Functional readouts: Compare using multiple functional parameters (binding affinity, signaling, biological responses)

• Structural analysis: Consider comparative modeling or experimental structure determination to identify key differences

• Domain swap experiments: Create chimeric receptors to identify which domains confer species-specific properties

How can researchers address the challenge of limited feline-specific reagents when studying IL2RA?

Practical strategies include:

• Cross-reactivity testing: Systematically evaluate human reagents for cross-reactivity with feline proteins

• Custom antibody development: Generate feline-specific antibodies using recombinant feline IL2RA as immunogen

• Peptide-based approaches: Design assays using conserved peptide regions that function across species

• Genetic tagging: Introduce epitope tags into endogenous feline IL2RA for detection with tag-specific reagents

• RNA-based detection: Develop species-specific PCR or RNA-seq approaches when protein detection is challenging

How does IL2RA contribute to signaling pathway specificity in different immune cell subsets?

IL2RA enhances IL-2 signaling through multiple mechanisms:

• Creating an extracellular IL-2 reservoir: IL2RA binds IL-2 and creates a cell-surface cytokine reservoir that can gradually feed into signaling complexes

• Receptor recycling: IL2RA undergoes internalization and recycling, contributing to sustained signaling

• Cell type-specific expression: Differential expression of IL2RA across immune cell types (high on regulatory T cells) leads to cell-specific responses to IL-2

• Competition for limited IL-2: High IL2RA expression enables cells to compete effectively for limited IL-2, particularly important for regulatory T cells

These mechanisms collectively allow IL2RA to fine-tune IL-2 responses across different immune cell populations.

What methods are most effective for measuring IL2RA-dependent signaling events?

Recommended approaches include:

• Phospho-flow cytometry: Measuring phosphorylation of STAT5 and other signaling proteins at the single-cell level

• Time-course analyses: Capturing the kinetics of signaling activation and decay

• Receptor occupancy assays: Quantifying IL-2 binding to cell surface receptors over time

• Gene expression profiling: Analyzing IL-2-responsive gene transcription

• Protein-protein interaction studies: Investigating the assembly and disassembly of receptor complexes

Experimental data has shown that IL2RA mediates temporal regulation of IL-2 signaling and enhances immunological memory, highlighting the importance of studying signaling dynamics rather than just steady-state responses .

How is recombinant IL2RA being utilized in cancer research?

Recent studies have revealed:

• Biomarker applications: IL2RA expression correlates with aggressiveness and stem cell-related properties in acute myeloid leukemia

• Therapeutic targeting: Anti-IL2RA therapy being explored in early-stage clinical trials for AML treatment

• Cancer immunotherapy: Modified IL-2/IL2RA interactions being developed to enhance anti-tumor immune responses

• Diagnostic applications: IL2RA being investigated as a potential biomarker for various cancers, similar to its use as a biomarker for non-alcoholic fatty liver disease

What novel approaches are being developed for modulating IL2RA-dependent immune responses?

Cutting-edge approaches include:

• Synthetic immunology: Engineering cells with modified IL2RA expression or signaling properties

• Targeted protein degradation: Using proteolysis-targeting chimeras (PROTACs) to selectively degrade IL2RA

• mRNA therapeutics: Delivering modified IL2RA mRNA to transiently alter receptor expression

• CRISPRa/CRISPRi: Using CRISPR activation or interference to modulate endogenous IL2RA gene expression

• Enhancer editing: Modifying IL2RA enhancer elements to alter cell-specific expression patterns